How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,467 results for

Medications that Exacerbate Heart Failure

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Acute exacerbation of congestive heart failure

Acute exacerbation of congestive heart failure Acute exacerbation of congestive heart failure - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Acute exacerbation of congestive heart failure Last reviewed: February 2019 Last updated: October 2018 Summary Clinical syndrome of reduced cardiac output, tissue hypoperfusion, increased pulmonary pressure, and tissue congestion. Presents with dyspnoea, decreased exercise (...) tolerance, swelling of the legs, fatigue, and generalised weakness. Clinical diagnosis is supported by ancillary tests such as ECG, chest x-ray, B-type natriuretic peptide, and echocardiogram. In cases where echocardiographic images are suboptimal or when an unusual cause of heart failure is suspected, and for diagnosis of specific cardiomyopathies, other tests (e.g., cardiac catheterisation with haemodynamic measurements, computed tomography, and cardiac magnetic resonance imaging) are used. Diuretics

2018 BMJ Best Practice

2. Acute exacerbation of congestive heart failure

Acute exacerbation of congestive heart failure Acute exacerbation of congestive heart failure - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Acute exacerbation of congestive heart failure Last reviewed: February 2019 Last updated: October 2018 Summary Clinical syndrome of reduced cardiac output, tissue hypoperfusion, increased pulmonary pressure, and tissue congestion. Presents with dyspnoea, decreased exercise (...) tolerance, swelling of the legs, fatigue, and generalised weakness. Clinical diagnosis is supported by ancillary tests such as ECG, chest x-ray, B-type natriuretic peptide, and echocardiogram. In cases where echocardiographic images are suboptimal or when an unusual cause of heart failure is suspected, and for diagnosis of specific cardiomyopathies, other tests (e.g., cardiac catheterisation with haemodynamic measurements, computed tomography, and cardiac magnetic resonance imaging) are used. Diuretics

2018 BMJ Best Practice

3. Drugs That May Cause or Exacerbate Heart Failure

Drugs That May Cause or Exacerbate Heart Failure Drugs That May Cause or Exacerbate Heart Failure | Circulation Search Hello Guest! Login to your account Email Password Keep me logged in Search March 2019 March 2019 March 2019 March 2019 March 2019 February 2019 February 2019 February 2019 February 2019 January 2019 January 2019 January 2019 January 2019 January 2019 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share (...) on Jump to Free Access article Drugs That May Cause or Exacerbate Heart Failure A Scientific Statement From the American Heart Association , PharmD, MSPH, FAHA, Chair , PharmD , MD, MSc , MD , MD, MSCE , MB ChB, FAHA , PharmD , and PhD, ACNP-BC, FAHA MD, FAHA, Co-ChairOn behalf of the American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular

Full Text available with Trip Pro

2016 American Heart Association

4. Medications that exacerbate Heart Failure

Medications that exacerbate Heart Failure Medications that Exacerbate Heart Failure Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 (...) Medications that Exacerbate Heart Failure Medications that Exacerbate Heart Failure Aka: Medications that Exacerbate Heart Failure , Congestive Heart Failure Exacerbation due to Medications , Drug-Induced CHF Exacerbation , Medications that Provoke Heart Failure From Related Chapters II. Causes: Cardiovascular Agents that exacerbate Heart Failure s (except ) Avoid , and Beta agonists Higher hospitalization and mortality rates in CHF May be started slowly once CHF is stable and compensated III. Causes

2018 FP Notebook

5. Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association

Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association | Circulation Search Hello Guest! Login to your account Email Password Keep me logged in Search March 2019 March 2019 March 2019 March 2019 March 2019 February 2019 February 2019 February 2019 February 2019 January 2019 January 2019 January 2019 January 2019 January (...) 2019 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share on Jump to Free Access article Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association , MD, Chair , MD, MS, FAHA, Co-Chair , MD , MD, PhD, FAHA , MD , MD , MD, MS , MD, MPH, FAHA , MD , MD, PhD, FAHA , and MD, FAHA MDOn behalf of the American Heart Association Council on Clinical Cardiology; Council

Full Text available with Trip Pro

2018 American Heart Association

6. Semaphorin 4D levels in heart failure patients: a potential novel biomarker of acute heart failure? (PubMed)

Semaphorin 4D levels in heart failure patients: a potential novel biomarker of acute heart failure? Semaphorin 4D (Sema4D) is expressed on platelets and T-cells and known to be involved in inflammation. The aims of this study include comparing Sema4D and N terminal pro brain natriuretic peptide (NT-proBNP) serum levels in heart failure (HF) patients to a control group, evaluating the correlation between Sema4D and NT-proBNP levels, and assessing Sema4D serum levels in HF patients during acute (...) exacerbation and remission.Forty-five patients diagnosed with HF (based on echocardiographic findings, positive NT-proBNP levels, and normal C-reactive protein) and 11 healthy controls (declaring no chronic diseases or medications) comprised the study population. Demographic, clinical, laboratory, and echocardiographic data were used to create the study database. NT-proBNP and Sema4D serum samples were taken on admission and discharge. NT-proBNP levels were significantly higher in the HF group than

Full Text available with Trip Pro

2018 ESC heart failure

7. Link-HF, Phase II: Multisensor Non-invasive Telemonitoring System for Prediction of Heart Failure Exacerbation

Link-HF, Phase II: Multisensor Non-invasive Telemonitoring System for Prediction of Heart Failure Exacerbation Link-HF, Phase II: Multisensor Non-invasive Telemonitoring System for Prediction of Heart Failure Exacerbation - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. Link-HF, Phase II: Multisensor Non-invasive Telemonitoring System for Prediction of Heart Failure Exacerbation (LINK-HF) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03037710 Recruitment Status : Completed First Posted : January 31

2017 Clinical Trials

8. De novo mitral regurgitation as a cause of heart failure exacerbation in patients with hypertrophic cardiomyopathy. (PubMed)

De novo mitral regurgitation as a cause of heart failure exacerbation in patients with hypertrophic cardiomyopathy. To determine the prevalence and mechanisms of de novo severe MR due to mitral valve structural abnormalities causing clinical deterioration in patients with HCM.This is an observational study based on HCM registry comprising consecutive HCM patients (n=397) who have been evaluated and followed in the Cardiomyopathy Clinic of Sheba Medical Center. Sixteen patients (4.0%), 8 males (...) . Fourteen underwent surgery; myxomatous changes were found in all excised valves (n=9). On age-adjusted univariate analysis, 3 clinical parameters remained significantly associated with the development of de novo MR, female gender, LVOT obstruction and significant MR at baseline. On multivariable analysis, only LVOT obstruction (HR=3.8) and MR at baseline evaluation (HR=8.2) predicted development of severe MR.De novo severe MR leading to acute heart failure was repeatedly observed in our HCM series

2017 International journal of cardiology

9. CardioMEMS for Heart Failure Monitoring

assume that patients would strongly prefer to avoid heart failure exacerbations and repeated heart failure hospitalizations. However, this preference would be tempered by the serious adverse event rate of 15/550 that includes events such as arrhythmias, bleeding, and shock. More rare but plausible concerns include infection, thrombosis, and device migration; the study might have been underpowered to detect these events. Given the noninvasiveness of alternatives (e.g., using a scale and communication (...) (0.74 to 1.03) p = 0.10 Deaths and all-cause admissions n = 604 1.65 events per patient-year n = 249 1.61 events per patient-year HR 0.97 (0.83 to 1.14) p = 0.75 Givertz et al., 2017 This study, derived from the previously described CHAMPION trial, reported the effectiveness of CardioMEMS™ in reducing the risk of hospitalization for heart failure or death among patients with reduced ejection fraction who were on at least one guideline-directed medical therapy at baseline. This analysis by baseline

2018 Oregon Health Evidence Review Commission

10. Heart failure

ischemia and infarction, volume loading caused by cardiac lesions associated with congenital heart disease and valvular pathologies, and pressure loading 2018 9. Drugs That May Cause or Exacerbate Heart Failure Drugs That May Cause or Exacerbate Heart Failure | Circulation Search for this keyword Search Search for this keyword Search Header Publisher Menu AHA Scientific Statement Drugs That May Cause or Exacerbate Heart Failure A Scientific Statement From the American Heart Association Robert L. Page (...) failure ( HF ). More recent evidence suggests that natriuretic peptides along with the next generation of biomarkers may provide added value to medical management, which could potentially 2017 11. Transitions of Care in Heart Failure Transitions of Care in Heart Failure | Circulation : Heart Failure Search for this keyword Search Search for this keyword Search Header Publisher Menu AHA Scientific Statement Transitions of Care in Heart Failure A Scientific Statement From the American Heart Association

2018 Trip Latest and Greatest

11. Patients Hospitalized with Heart Failure: Risk Assessment, Management, and Clinical Trajectory

judgment in accordance with patient preferences. 5. These algorithms are based on the best available data, but given the relatively limited current data concern- ing a number of aspects of the HF hospitalization, they will require revision as new data emerge. 3.1. De?nitions GDMT: Guideline-directed medical therapy Optimal therapy: Treatment provided at either the target or the highest tolerated dose for a given patient. EF: Ejection fraction HFrEF: Heart failure with reduced left ventricular ejection (...) or by palliative care specialists may be FIGURE 1 Clinical Course of Heart Failure Improving towards target Improving towards target Not improved/ worsening Stalled Focus of Care Transition to Oral Therapies Admission Discharge First Follow-up Visit Clinical decompensation Discharge coordination Ongoing optimization of outpatient care Guideline-directed medical therapy Evaluation for long-term trajectory Early acute phase Late acute phase Optimization phase Early post- discharge phase Transition to chronic

2019 American College of Cardiology

12. Type 2 Diabetes Mellitus and Heart Failure

underscored that HF is a critical outcome in patients with DM and suggest that glucose-lowering medications may influence the risk of HF development and progression. The purpose of this American Heart Association/Heart Failure Society of America joint scientific statement is to summarize current understanding of the epidemiology, pathophysiology, and outcomes of patients with type 2 DM and HF. In addition, it provides a review of contemporary data on the efficacy and safety of pharmacological (...) . Associations of glycemic medications with risks of cardiovascular events and heart failure hospitalization. The risks of major adverse cardiovascular events ( left ) and heart failure hospitalization ( right ) in the cardiovascular outcomes trials are shown. Trials of GLP-1 (glucagon-like peptide 1) receptor agonists are shown in blue, DPP-4 (dipeptidyl peptidase-4) inhibitors in red, and SGLT-2 (sodium glucose cotransporter type 2) inhibitors in green. The EXAMINE trial (Examination of Cardiovascular

2019 American Heart Association

13. Chronic Heart Failure in Congenital Heart Disease

Chronic Heart Failure in Congenital Heart Disease Chronic Heart Failure in Congenital Heart Disease | Circulation Search Hello Guest! Login to your account Email Password Keep me logged in Search October 2019 September 2019 August 2019 July 2019 June 2019 May 2019 April 2019 March 2019 February 2019 January 2019 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share on Jump to Free Access article Chronic Heart Failure (...) cardiac complications, including heart failure (HF). HF management in the setting of CHD is challenged by the wide range of ages at which HF occurs, the heterogeneity of the underlying anatomy and surgical repairs, the wide spectrum of HF causes, the lack of validated biomarkers for disease progression, the lack of reliable risk predictors or surrogate end points, and the paucity of evidence demonstrating treatment efficacy. The purposes of this statement are to review the literature pertaining

2016 American Heart Association

14. Evaluation and Management of Right-Sided Heart Failure

Evaluation and Management of Right-Sided Heart Failure Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association | Circulation Search Hello Guest! Login to your account Email Password Keep me logged in Search March 2019 March 2019 March 2019 March 2019 March 2019 February 2019 February 2019 February 2019 February 2019 January 2019 January 2019 January 2019 January 2019 January 2019 Free Access article Share on Jump to Free Access article (...) Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association , MD, Chair , MD, MS, FAHA, Co-Chair , MD , MD, PhD, FAHA , MD , MD , MD, MS , MD, MPH, FAHA , MD , MD, PhD, FAHA , and MD, FAHA MDOn behalf of the American Heart Association Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; and Council on Cardiovascular Surgery and Anesthesia Marvin A. Konstam , Michael S. Kiernan , Daniel Bernstein , Biykem Bozkurt , Miriam

Full Text available with Trip Pro

2018 International Society for Heart and Lung Transplantation

15. Heart Failure

regarding the use of implantable cardioverter defibrillators. Weak FOR Low Transthoracic echocardiography should be considered in patients with heart failure with reduced ejection fraction (HFrEF) 3–6 months after the start of optimal medical therapy, or if there has been a change in clinical status, to assess the appropriateness for other treatments, including device therapy (implantable cardioverter defibrillator [ICD] or cardiac resynchronisation therapy [CRT], or both). Weak FOR Low Acute heart (...) in patients with heart failure associated with high-risk features, to decrease mortality and rehospitalisation. Strong FOR High In areas where access to a face-to-face multidisciplinary heart failure disease-management program after discharge is limited, patients should be followed up with a multidisciplinary telemonitoring or telephone support program. Strong FOR Moderate Nurse-led medication titration is recommended in patients with HFrEF who have not achieved maximum tolerated doses of ACE inhibitors

2018 Cardiac Society of Australia and New Zealand

16. Management of chronic heart failure

and/or MRI of the renal arteries). 5.18 HEART FAILURE AND ANGINA Beta blockers are the drug of choice in patients with HF and angina (see the SIGN guideline on the management of stable angina). 125 Sublingual and oral nitrate preparations may also be used safely for the treatment of anginal symptoms where blood pressure permits. Calcium channel blockers (with the exception of amlodipine) 126 have been found to exacerbate symptoms of heart failure or increase mortality after myocardial infarction (...) Management of chronic heart failure SIGN 147 • Management of chronic heart failure A national clinical guideline March 2016 Evidence www.healthcareimprovementscotland.org Edinburgh Office | Gyle Square |1 South Gyle Crescent | Edinburgh | EH12 9EB Telephone 0131 623 4300 Fax 0131 623 4299 Glasgow Office | Delta House | 50 West Nile Street | Glasgow | G1 2NP Telephone 0141 225 6999 Fax 0141 248 3776 The Healthcare Environment Inspectorate, the Scottish Health Council, the Scottish Health

2016 SIGN

17. Medications that exacerbate Heart Failure

Medications that exacerbate Heart Failure Medications that Exacerbate Heart Failure Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 (...) Medications that Exacerbate Heart Failure Medications that Exacerbate Heart Failure Aka: Medications that Exacerbate Heart Failure , Congestive Heart Failure Exacerbation due to Medications , Drug-Induced CHF Exacerbation , Medications that Provoke Heart Failure From Related Chapters II. Causes: Cardiovascular Agents that exacerbate Heart Failure s (except ) Avoid , and Beta agonists Higher hospitalization and mortality rates in CHF May be started slowly once CHF is stable and compensated III. Causes

2016 FP Notebook

18. Rehospital Delay, Precipitants of Admission, and Length of Stay in Patients With Exacerbation of Heart Failure. (PubMed)

and length of hospital stay.All admissions in 12 full months to a tertiary medical center were reviewed if the patient had a discharge code related to heart failure. Data on confirmed admissions for exacerbation of heart failure were included in the study. Electronic and paper medical records were reviewed to identify how long it took patients to seek care after they became aware of signs and symptoms, factors that precipitated exacerbation, and discharge details.Exacerbation of heart failure (...) , recent change in heart failure medicine, renal failure, poor medication adherence, and hypertension are risk factors for hospitalizations for exacerbation of heart failure.©2016 American Association of Critical-Care Nurses.

Full Text available with Trip Pro

2016 American Journal of Critical Care

19. Congestive Heart Failure Exacerbation Management

-compliance is most common cause Noncompliance with chronic CHF medications Excess dietary intake s s Excess dosing of newly started medication (e.g. , ) High output Severe X. Differential Diagnosis: Acute Congestive Heart Failure Exacerbation See Exacerbation Most difficult to distinguish acutely as cause Initial treatment of both and CHF concurrently if appear equally plausible Many emergency protocols advocate this approach Consider the use of to exclude when the is non-diagnostic Medication induced (...) Congestive Heart Failure Exacerbation Management Congestive Heart Failure Exacerbation Management Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer

2018 FP Notebook

20. Clinical Question: Can Ventolin improve wheeze in heart failure?

of asthma or COPD. Case Resolution The Paramedics identified the patient as being in severe heart failure. History and physical exam findings strongly supported an acute CHF exacerbation. Management en route included supplemental oxygen and SL nitroglycerin (0.4mg). In consultation with a physician, CPAP was initiated. 7 The patient was admitted for heart failure secondary to medication non-compliance. This post was copy-edited and uploaded by . References 1. LOMBARDO T, HARRISON T. Cardiac asthma (...) pulmonary function, hemodynamic stability, and fluid clearance from the alveolar space, but also noted side effects including hypokalemia, tachycardia, and dysrhythmias. Adverse cardiac events such were also noted with chronic administration. The limitation of this study is that the majority of individuals being treated were in compensated heart failure 5 and can not necessarily be extrapolated to patients with acute decompensated heart failure patients. Another review analyzed the use of HF medications

2017 CandiEM

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>